Avalo Therapeutics receives Nasdaq delisting notice for negative stockholders' equity of $112.6M

Avalo Therapeutics, Inc.

Reported stockholders' equity of negative $112.6M in Q1 2024 10-Q, below $2.5M minimum.
Has 45 days (until July 5, 2024) to submit a compliance plan to Nasdaq Staff.
If plan accepted, Staff may grant up to 180-day extension to regain compliance.
No immediate effect on listing; common stock continues trading on Nasdaq under AVTX.
Company evaluating options; no assurance of regaining compliance or avoiding delisting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.